Malignant Peritoneal Mesothelioma With EWSR1-ATF1 Fusion: A Case Report

Helen Ke; Anthony J Gill; Catriona McKenzie; James G Kench; Renee C F Chan; Nick Pavlakis; Michael Fulham; Cherry Koh; Steven Kao

doi:10.1016/j.jtocrr.2021.100236

Malignant Peritoneal Mesothelioma With EWSR1-ATF1 Fusion: A Case Report

JTO Clin Res Rep. 2021 Oct 11;2(11):100236. doi: 10.1016/j.jtocrr.2021.100236. eCollection 2021 Nov.

Authors

Helen Ke^{1

2}, Anthony J Gill^{1

3

4}, Catriona McKenzie^{1

5}, James G Kench^{1

5}, Renee C F Chan⁶, Nick Pavlakis^{1

7}, Michael Fulham^{1

8}, Cherry Koh^{9

10

11}, Steven Kao^{1

2

12}

Affiliations

¹ University of Sydney, Sydney, Australia.
² Asbestos Diseases Research Institute, Concord, Australia.
³ Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, Australia.
⁴ NSW Health Pathology, Department of Anatomical Pathology Royal North Shore Hospital, St Leonards, Australia.
⁵ NSW Health Pathology, Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia.
⁶ Electron Microscopy Unit, Department of Anatomical Pathology, Concord Hospital, Concord, Australia.
⁷ Department of Medical Oncology, Royal North Shore Hospital, St Leonards, Australia.
⁸ Department of Molecular Imaging, Royal Prince Alfred Hospital, Sydney, Australia.
⁹ Department of Colorectal Surgery, Royal Prince Alfred Hospital, Sydney, Australia.
¹⁰ Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, Sydney, Australia.
¹¹ Discipline of Surgery, Faculty of Medicine, and Health, University of Sydney, Sydney, Australia.
¹² Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, Australia.

Abstract

Malignant mesothelioma with EWSR1-ATF1 fusion is a rare malignancy described in young adults without asbestos exposure. To the best of our knowledge, outcomes to local and systemic therapies for this subtype of malignant mesothelioma have not been described. This case report describes the clinical course of a 19-year-old man diagnosed with malignant peritoneal mesothelioma with EWSR1-ATF1 fusion localized to the abdomen. His disease followed an aggressive course and resulted in limited survival (18 mo). There was treatment resistance to several lines of conventional local and systemic treatments for peritoneal mesothelioma and biologically targeted MET inhibition with crizotinib. More research is required in this rare subtype of peritoneal mesothelioma.

Keywords: ATF1; Case report; EWSR1; Peritoneal mesothelioma.

Publication types

Case Reports